FDA’s voluntary program to rate the maturity of a manufacturer’s quality management practices beyond baseline CGMP compliance — created to help reduce drug shortages and recalls and signal manufacturing reliability. Assessed across five practice areas on a 10-point scale.
CGMP compliance is a floor: a site either meets the requirements or it does not. QMM asks a different question — how reliably and how well is this organisation managed for quality? The motivation is supply reliability. FDA’s analysis of drug shortages repeatedly found that shortages trace back to manufacturing and quality failures at facilities that were nominally compliant, so a binary pass/fail signal was not distinguishing robust operations from fragile ones.
FDA assesses maturity across five practice areas: Management Commitment to Quality, Business Continuity, Technical Excellence, Advanced Pharmaceutical Quality System, and Employee Empowerment and Engagement. The framing deliberately reaches past documentation into culture and management behaviour — whether problems surface early, whether staff have genuine authority to stop the line, whether the site plans for disruption rather than reacting to it.
It is a voluntary programme, not a regulation, and a QMM rating does not replace inspection or CGMP obligations. Its intended value is as a market and management signal: a way for purchasers to weigh reliability alongside price, and for manufacturers to see where their quality system is mature versus merely compliant. SPEQ’s maturity assessment maps its scored domains onto these practice areas — a SPEQ interpretation, not an FDA rating.
- —Measures how well quality is managed, beyond the binary of CGMP compliance.
- —Five practice areas: Management Commitment to Quality · Business Continuity · Technical Excellence · Advanced Pharmaceutical Quality System · Employee Empowerment and Engagement.
- —Motivated by drug shortages, which trace to quality and manufacturing failures at compliant sites.
- —Voluntary — it does not replace inspection or CGMP obligations.
- —Reaches into culture and management behaviour, not just documentation.
- —Intended as a reliability signal for purchasers and a management lens for manufacturers.
FDA CDER Quality Management Maturity programme (voluntary; developed following the FDA Drug Shortages report, 2019). Complementary to ICH Q10 (Pharmaceutical Quality System) and the CGMP requirements of 21 CFR 210/211, which it does not replace.
Frequently asked questions
What does QMM stand for?
QMM stands for Quality Management Maturity (FDA CDER).
What is QMM?
FDA’s voluntary program to rate the maturity of a manufacturer’s quality management practices beyond baseline CGMP compliance — created to help reduce drug shortages and recalls and signal manufacturing reliability. Assessed across five practice areas on a 10-point scale.
Which regulations cover QMM?
FDA CDER Quality Management Maturity programme (voluntary; developed following the FDA Drug Shortages report, 2019). Complementary to ICH Q10 (Pharmaceutical Quality System) and the CGMP requirements of 21 CFR 210/211, which it does not replace.
SPEQ decodes published regulatory concepts in plain language. Definitions are a practitioner reference, not legal or regulatory advice.
Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.